4,036 members and growing
HCSA LONDON & SOUTH REGIONAL EIS EVENT AWARDS OPEN NOW in London 18th April Holiday Inn, Regents Park,
2024 HCSA MIDLANDS REGIONAL EIS EVENT AWARDS OPEN NOW in Daventry 9th May Staverton Park Hotel,
2024 HCSA NORTH REGIONAL EIS EVENT AWARDS OPENING SOON in Leeds 4th July Queens Hotel , LIVE SOON
Women's Network Conference Holiday Inn Regents Park 4th September 2024, Opening Late April 2024
HCSA Annual Conference 13 & 14 November 2024 Telford International Centre ON SALE SOON BOOK EARLY to save disappointment
Close Search

Smith & Nephew has now completed the acquisition of a developer of knee cartilage regeneration in a deal worth up to $330 million.

The bolt-on purchase of CartiHeal, the developer of Agili-C, a sports medicine technology, was announced in November, but with the i’s dotted and t’s crossed, Scott Schaffner, Smith & Nephew’s president of sports medicine, vowed that the company’s “expertise in regenerative therapy and leadership in knee repair gives me great confidence that this will be a significant value creator” for Smith & Nephew.

Long-suffering investors in the veteran FTSE 100 company will hope that its bosses are right and that bolt-on acquisitions such as CartiHeal can help not only regenerate frail knees but also the company’s financial performance and limping share price.

Read full article

Source: The Times

Date: 15 January

Posted in News on Jan 14, 2024

Back to News